trial
as of 2026-07-01Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
NCTId NCT04779177
at a glance
Phase 1 · Completed
Enrollment 26 (actual)
Sponsored by Intra-Cellular Therapies, Inc.
Primary completion 2022-07-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
26 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Sequential
Masking
None
Start
2021-03-12
Primary completion
2022-07-30
Eligibility
ALL · 13 Years · 17 Years
Interventions & indications
Indications
Sponsors
Intra-Cellular Therapies, Inc.Lead Sponsor
Investigators
1
Clinical SitePrincipal Investigator
Sites
3 total
Hollywood, United StatesAtlanta, United StatesDecatur, United States
Facts & assertions
4 sourced
Enrollment
26
Phase
PHASE1
Primary Completion Date
2022-07-30
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
indication
investigator
person